1,2,3,4,6-Pentagalloyl Glucose, a RBD-ACE2 Binding Inhibitor to Prevent SARS-CoV-2 Infection
The outbreak of SARS-CoV-2 virus caused more than 80,155,187 confirmed COVID-19 cases worldwide, which has posed a serious threat to global public health and the economy. The development of vaccines and discovery of novel drugs for COVID-19 are urgently needed. Although the FDA-approved SARS-CoV-2 v...
Main Authors: | Rui Hong Chen, Li Jun Yang, Sami Hamdoun, Sookja Kim Chung, Christopher Wai-kei Lam, Kai Xi Zhang, Xiaoling Guo, Chenglai Xia, Betty Yuen Kwan Law, Vincent Kam Wai Wong |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-03-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2021.634176/full |
Similar Items
-
Identification of potential SARS-CoV-2 entry inhibitors by targeting the interface region between the spike RBD and human ACE2
by: Arun Bahadur Gurung, et al.
Published: (2021-02-01) -
Biomechanical Restoration Potential of Pentagalloyl Glucose after Arterial Extracellular Matrix Degeneration
by: Sourav S. Patnaik, et al.
Published: (2019-07-01) -
Targeted delivery of pentagalloyl glucose inhibits matrix metalloproteinase activity and preserves elastin in emphysematous lungs
by: Vaideesh Parasaram, et al.
Published: (2021-09-01) -
Animal Model Dependent Response to Pentagalloyl Glucose in Murine Abdominal Aortic Injury
by: Jennifer L. Anderson, et al.
Published: (2021-01-01) -
A novel screening strategy of anti-SARS-CoV-2 drugs via blocking interaction between Spike RBD and ACE2
by: Xiaoning Wang, et al.
Published: (2021-02-01)